Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
HGF CRISPR/Cas9 KO Plasmid (h): sc-400433
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HGF CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the HGF genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: HGFα Antibody (H-10): sc-374422
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HGF CRISPR/Cas9 KO Plasmid (h) | sc-400433 | 20 µg | $397.00 |
Overview
Hepatocyte growth factor (HGF) is a secreted pleiotropic cytokine that binds the MET receptor tyrosine kinase to regulate epithelial–mesenchymal communication, cell motility, survival, proliferation, and morphogenesis. HGF–MET signaling engages MAPK/ERK, PI3K–AKT, STAT, and Rho-family GTPase pathways to coordinate tissue remodeling, wound repair, and organ development. Dysregulated HGF expression or aberrant pathway activation is linked to invasive growth programs, stromal–tumor interactions, and altered angiogenic and inflammatory microenvironments across multiple disease contexts. As a paracrine factor produced by mesenchymal cells, HGF is frequently studied in co-culture and conditioned media systems to interrogate microenvironment-driven signaling dynamics.
HGF CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the HGF gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the HGF together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the HGF open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish HGF protein expression.
This CRISPR knockout system enables efficient generation of HGF-deficient cell models for investigation of HGF signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting HGF exon(s) critical for HGF function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple HGF genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by HGF CRISPR/Cas9 KO Plasmid (h) and HGF CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the HGF locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by HGF HDR Plasmid (h) and HGF HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by HGF homology arms to support homology-directed repair at defined HGF target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.